Company intelligence / Profile preview

SYSNAV

Vernon, Normandy, Francehealthcare.sysnav.com ↗

Ownership: Private
Development stage: Commercial

Overview

SYSNAV Healthcare has developed ActiMyo and Syde wearable devices based on proprietary magneto-inertial technology. These enable precise, real-world measurement of patient motor function. The SV95C digital endpoint—stride velocity 95th centile—was the first-ever digital endpoint qualified by the European Medicines Agency as a primary outcome measure for ambulant Duchenne muscular dystrophy patients in superiority studies. Their solutions are being adopted as regulatory-grade endpoints in neuromuscular disease clinical trials.

Therapeutic areas: Neurology
Modalities: DeviceWearable sensor technology
Industry: Physiological Monitoring

Partnerships

Roche (multi-year partnership to co-develop new regulatory-grade digital endpoints for movement disorders using SYSNAV’s wearable biosensor platform)

Beyond the preview

Go deeper on SYSNAV.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYSNAV.

Explore the full profile